Xeris Pharmaceuticals Inc (XERS) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $8.20 (+0.49%), Market cap $1.10B, P/E ratio 91.14, 52-week low–high $4.35 ~ $9.90.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for
Financial statements, price targets, institutional (13F) holdings and related news for Xeris Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Xeris Pharmaceuticals Inc trades at $8.20 (+0.49%). Real-time quotes and charts are available on BlackAll Trade.
Xeris Pharmaceuticals Inc has a market cap of about $1.10B. Its P/E ratio is 91.14.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers